AU2005206098B2 - System and method for treating abnormal epithelium in an esophagus - Google Patents
System and method for treating abnormal epithelium in an esophagus Download PDFInfo
- Publication number
- AU2005206098B2 AU2005206098B2 AU2005206098A AU2005206098A AU2005206098B2 AU 2005206098 B2 AU2005206098 B2 AU 2005206098B2 AU 2005206098 A AU2005206098 A AU 2005206098A AU 2005206098 A AU2005206098 A AU 2005206098A AU 2005206098 B2 AU2005206098 B2 AU 2005206098B2
- Authority
- AU
- Australia
- Prior art keywords
- energy
- esophagus
- energy delivery
- balloon
- delivery structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0538—Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/107—Measuring physical dimensions, e.g. size of the entire body or parts thereof
- A61B5/1076—Measuring physical dimensions, e.g. size of the entire body or parts thereof for measuring dimensions inside body cavities, e.g. using catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
- A61B5/4222—Evaluating particular parts, e.g. particular organs
- A61B5/4233—Evaluating particular parts, e.g. particular organs oesophagus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/06—Electrodes for high-frequency therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/0016—Energy applicators arranged in a two- or three dimensional array
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00482—Digestive system
- A61B2018/00494—Stomach, intestines or bowel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00577—Ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00696—Controlled or regulated parameters
- A61B2018/00738—Depth, e.g. depth of ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00791—Temperature
- A61B2018/00797—Temperature measured by multiple temperature sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
Abstract
Various embodiments of the invention provide a system for treating abnormal mucosa in an esophagus comprising an elongated member; an energy delivery structure deployable from the elongated member and adapted to engage a circumferential section of a mucosal lining of the esophagus to deliver energy to the section; and means for delivering energy through the delivery structure under conditions selected to initiate regrowth of a mucosal layer without substantial injury to a sub-mucosal layer underlying the mucosal layer. By injuring or necrosing metaplastic or other abnormal mucosal cells, regrowth of the mucosa substantially free from abnormal cells can be initiated. In an embodiment, the energy delivery structure can include an RF electrode array positioned on a surface of the structure and configured to be coupled to an RF power supply.
Description
SYSTEM AND METHOD FOR TREATING ABNORMAL EPITHELIUM IN AN ESOPHAGUS 5 BACKGROUND OF THE [NVENTION 100011 1. Field of the Invention. A system and method for treating abnormal epithelium in an esophagus. 100021 Two of the major functions of the human esophagus are the transport of food from intake to the stomach and the prevention of retrograde flow of gastrointestinal contents. The 10 retrograde flow is, in part, prevented by two esophageal sphincters which normally remain closed and which are functional rather than distinct entities. In particular, a lower esophageal sphincter nonnally remains closed until parasympathetic activation causes its relaxation, allowing food to pass into the stomach from the esophagus. Various types of food and other activity may cause relaxation of the sphincter, such as fatty meals, smoking and beverages 15 having xanthene content. Certain drugs or pharmaceuticals also may cause relaxation of this lower esophageal sphincter, as well as localized trauma or other problems such as neuromuscular disorders. 100031 Regardless, patients having such difficulties may present with clinical indications including dysphagia, or difficulty in swallowing, as well as more classic symptoms of 20 heartburn and other similar complaints. Recurrent problems of this nature often lead to a disorder known as reflux esophagitis, consisting of esophageal mucosa damage due to the interaction of the gastric or intestinal contents with portions of the esophagus having tissue not designed to experience such interaction. As suggested above, the causative agent for such problems may vary.
2 OBJECT OF THE INVENTION It is the object of the present invention to substantially overcome or ameliorate one 5 or more of the disadvantages of the prior art. SUMMARY OF THE INVENTION The present invention provides a system for treating mucosal tissue in an esophagus, said system comprising: an elongated member; an arcuate energy delivery 10 structure deployable from the elongated member and adapted to engage a circumferential section of a mucosal lining of the esophagus to deliver energy to the section, wherein the circumferential section is less than 3600; and means for delivering energy through the delivery structure to initiate regrowth of a mucosal layer without substantial injury to a sub-mucosal layer underlying the mucosal layer. 15 Preferably, the circumferential section is less than about 1800. Preferably, the circumferential section is less than about 900. Preferably, the energy delivery structure is rotatable so as to sequentially treat different circumferential sections of the mucosal lining of the esophagus. Preferably, the energy delivery structure comprises an expandable structure 20 deployable from the elongated member, the expandable structure comprising an expandable balloon, and at least a portion of the balloon is non-distensible and dimensionally stable. Preferably, the energy delivery structure further comprises an electrode array. Preferably, the energy delivery structure comprises an expandable balloon 25 deployable from the elongated member and the electrode array comprises bipolar electrode pairs formed over a portion of the outer surface of the balloon, and a spacing between the electrodes is no more than 3 mm. Preferably, the electrodes are aligned circumferentially over the balloon. Preferably, the system further includes an expandable structure comprising a 30 frame deployable from the elongated member and an electrode array formed over at least a portion of the frame. Preferably, the frame comprises an arcuate surface which carries the electrodes to engage the circumferential section.
3 Preferably, the frame comprises two oppositely facing arcuate surfaces. Preferably, the energy delivery structure comprises a heating structure. Preferably, the heating structure comprises a radiation heat source. 5 Preferably, the energy delivery structure further comprises a pair of expandable centering elements for centering the energy delivery structure in the esophagus and disposed distally and proximally of the radiation heat source. In one embodiment, the energy delivery means comprises a photonic source. In one embodiment, the energy delivery means comprises a radiofrequency power 1o supply. Preferably, the radiofrequency power supply is adaptable to deliver an energy dosage in the range from I J/cm 2 to 50 J/cm 2 over a time period less than 5 seconds. Preferably, the radiofrequency power supply is configured to deliver a pulse of energy to the energy delivery structure that produces a heating profile in esophageal tissue is wherein engaged mucosal tissue is heated to a level sufficient to disable cell replication and submucosal tissue underlying the engaged mucosal tissue is not. Preferably, the energy delivery structure comprises an arcuate energy delivery structure deployable from the elongated member, the arcuate structure having a shape configured to engage only a partial circumferential section of the surface of the 20 esophagus. Preferably, the energy delivery structure comprises a radiofrequency electrode array coupled to theradiofrequency power supply, the array positioned on a surface of the energy delivery structure. Preferably, the energy pulse is less than about I second in duration. 25 Preferably, the energy delivery structure is configured to deliver at least one form of energy selected from the group consisting of radiofrequency energy, thermal energy, microwave energy, ultrasonic energy, infrared and ultraviolet radiation. In one embodiment, the energy delivered comprises radiofrequency energy.
4 Preferably, the energy delivery structure comprises an array of bipolar electrode pairs. Preferably, the electrodes have a width in the range from 0.1 mm to 3 mm and are 5 spaced apart by a distance in the range from 0.1 mm to 3 mm. A treatment catheter containing an energy delivery device and method of use are provided to access and treat portions of the human esophagus, particularly those suffering from or at risk of experiencing undesired growth of columnar epithelium. The catheter system and method provides for a controlled depth of injury and/or ablation of the io mucosal layer of the esophagus, typically using radiofrequency energy, non-ionizing ultraviolet radiation, microwave radiation, thermal energy (including both heating and cooling), ultrasonic energy, light energy (optionally combined with the use of photosensitizers), and the like. The present invention is particularly intended and adapted to treat the mucosal layer of the esophageal wall with minimal or no damage to the is underlying submucosal layer. In this way, a normal mucosal layer, i.e., substantially free from metaplastic and other damaged cells characteristic of disorders, such as Barrett's esophagus or metaplasia can regenerate. In particular, by ablating the mucosal layer of the esophagus and suppressing or eliminating acid intrusion into the lower esophagus over the esophageal sphincter during healing, the injured or necrosed mucosal cells will be 20 replaced with normal mucosal cellular growth. The method for treating abnormal mucosa in an esophagus comprises positioning an energy delivery device within the esophagus. Energy is delivered from the device under conditions selected to injure or necrose the mucosal layer and to initiate regrowth of a normal mucosal layer without causing substantial injury to the submucosal layer 25 underlying the mucosal layer. Typically, the total energy per square cm delivered to the esophageal tissue will be in the range from I J/cm 2 to 50 J/cm 2 , usually being from 5 J/cm to 15 J/cm . In order to effectively ablate the mucosal lining of the esophagus and allow re-growth of a normal mucosal lining without creating damage to underlying tissue structures, it is preferable to deliver the radiofrequency energy over a short time span in 30 order to reduce the effects of thermal conduction of energy to deeper tissue layers, thereby creating a "searing" effect. It is preferable to deliver the radiofrequency energy within a time span of less than 5 seconds. An optimal time for effective treatment is less than I second, and preferably less than 0.5 second or 0.25 seconds. The lower bound on time may be limited by the ability of the RF power source to deliver high powers. Since 3s the electrode area and consequently the tissue treatment area can be as much as several 5 square centimeters, RF powers of several hundred watts would be required in order to deliver the desired energy density in short periods of time. This may pose a practical limitation on the lower limit of time. However, an RF power source configured to deliver s a very short, high power, pulse of energy could be utilized. Using techniques similar to those used for flash lamp sources, or other types of capacitor discharge sources, a very high power, short pulse of RF energy can be created. This would allow treatment times of a few milliseconds or less, e.g. less than about 5 milliseconds. While this type of approach is feasible, in practice a more conventional RF source with a power capability of several 1o hundred watts may be preferred. Thus, for a power supply with a given maximum power capability, the time (t) needed to deliver the targeted total energy dosage (E) may be calculated by dividing the total energy by the available power (P), where the total energy dosage E is equal to the targeted energy density per unit area multiplied by the treatment area. 15 E t= = P It is presently believed that energy delivery under these conditions will raise the temperature of the mucosal tissue to a temperature sufficient to disable the cell replication mechanisms, typically from about 65'C to 851C, without raising the temperature of the 20 submucosal tissues to that level. Such selective heating is achieved by rapid delivery of relatively high power levels. While this heating profile is offered to help explain the underlying mechanism of the present invention, the mechanism may not be entirely accurate and is not essential to the performance or success of the present invention. In order to treat Barrett's esophagus or metaplasia, the energy delivery device will 25 usually be positioned within the lower esophagus at a location just above the lower esophageal sphincter (LES). Usually, the energy delivery device will be positioned to deliver energy around a circumferential mucosal surface having a length in the axial direction, within the esophagus of from 1 cm to 15 cm, usually from 1 cm to 8 cm, located above the lower esophageal sphincter. The length of the area of the esophagus to 30 treat above the LES will usually be determined by visual examination using an endoscope. The treatment will be effected using an energy applicator in one or more treatment steps, depending on the length of the applicator head which delivers energy. The energy may be delivered to different circumferential and/or axial sections of the esophageal wall sequentially. In either case, the energy may be delivered in an amount 35 and over a time sufficient to necrose tissue or, alternatively, sufficient only to injure the 5a mucosal layer without substantial necrosis. Preferably, injury to the underlying submucosal region will be limited or avoided entirely. In particular, it is desirable to limit the depth of injury or necrosis to the submucosal and deeper tissues to permit rapid s healing and to avoid stricture formation in theses tissues. In an exemplary embodiment, the energy delivered to the esophageal mucosa comprises radiofrequency energy. The radiofrequency energy can be delivered from the energy delivery device in a number of ways. Usually, the radiofrequency energy will be delivered in a bipolar fashion from a bipolar array of electrodes positioned on the energy io delivering device, typically on an expandable structure, such as a balloon, frame, cage, or the like, which can expand and deploy the electrodes directly against or immediately adjacent to the mucosal tissue (e.g., through direct contact or through a dielectric membrane or other layer). Alternatively, the energy delivery device may comprise a monopolar electrode structure which is energized by a radiofrequency power supply in is combination with a return electrode typically positioned on the patient's skin, e.g., on the small of the back. In either case, the radiofrequency energy will typically be delivered at a high energy flux over a very short period of time in order to injure or ablate only the mucosal layer without substantially heating or otherwise damaging the submucosal tissue. In particular embodiments, the radiofrequency energy is delivered by an array of 20 bipolar electrode pairs formed over the expandable structure, where each electrode typically has a width of less than 3 mm, usually in the range from 0.1 mm to 3 mm, preferably from 0.1 mm to 0.3 mm, and where the adjacent electrodes are spaced apart by a interelectrode distance of less than 3 mm, usually in the range from 0.1 mm to 3 mm, typically from 0.1 mm to 0.3 mm. Usually, the interelectrode spacing will be 25 approximately equal to the widths of the adjacent electrodes. In the illustrated embodiments, the widths of all electrodes will usually be equal, but it would be possible to use individual electrodes having different widths within the ranges set forth above. In all cases, the very close spacing of the bipolar electrode pairs assures that the current and resulting ohmic heating of the tissue is limited to a very shallow depth so that injury and 30 heating of the submucosal layer are minimized. In a preferred embodiment, the expandable structure is a non-distensible balloon which provides a dimensionally stable carrier for the electrode array. Thus, as the balloon is expanded, the spacing and configuration of the electrodes on the non-distensible balloon remain constant. 35 Usually, the electrodes will be configured on the balloon or other expandable structure so that they directly contact the mucosal tissue when deployed. In other 5b instances, however, the electrodes may be positioned on the inside surface of the balloon or other structure so that they do not directly engage the tissue. When not directly engaging the tissue, the balloon or other structure will be composed of a dielectric s material, and the radiofrequency energy will be delivered across the dielectric to provide the ohmic heating in the tissue. Other preferred methods of the present invention rely on delivering thermal energy to the mucosal layer. Preferably, the thermal energy is transferred by radiation from a high temperature source, typically an element heated to a temperature above I 000 0 C. 10 Suitable radiators include filaments, spherical radiators, cylindrical radiators, polygonal radiators, and the like. The radiators will be positioned to avoid direct contact with the esophageal wall. For example, the radiator may be positioned between two expansible balloons or other supports in order to align the radiator centrally within the esophageal lumen. Alternatively, the radiator may be positioned within a supporting balloon or other is inflatable structure, where the structure is transparent to the radiated energy. As mentioned above, systems for treating mucosal tissue in an esophagus comprise an elongated member, an energy delivery structure, and an energy delivery source. The elongated member is typically in the form of a catheter or tube adapted to be delivered transorally into the esophagus. Often, the elongated member may include working 20 channel(s), optical viewing capability, radiopaque markers, and other conventional structural features associated with esophageal probes. The energy delivery structure may be adapted to deliver any of the energy sources listed above, including radiofrequency energy, thermal energy (including heating and cooling), microwave energy, ultraviolet energy, ultrasonic energy, light energy, and the 25 like. The nature of the energy delivery apparatus will depend on the type of energy being delivered through the energy delivery structure. In the case of radiofrequency energy, the energy delivery apparatus will comprise a radiofrequency power supply together with control circuitry (analog or digital) which is adapted to deliver radiofrequency energy in the ranges and for the times described above. For thermal heating, the energy delivery 30 apparatus will comprise a power supply, optionally including temperature control circuitry, for heating an associated heating element. Generally, for all energy delivery structures, it is expected that the total energy dosages per cm 2 delivered will be within the ranges set forth above. The energy delivery structures of the treatment systems of the present invention will 35 typically comprise an expandable structure, such as an expandable balloon, for engaging electrodes or other components of the energy delivery structure directly against the mucosal WO 2005/070316 PCT/US2005/000432 tissue, or in the case of high temperature or other radiative sources, spaced a distance from the mucosal wall. Usually, the structure will comprise a non-distensible and dimensionally stable balloon which carries the electrodes in a fixed geometry which does not change as the structure is expanded. Alternatively, the expansible structure may comprise an electrically 5 conductive elastic balloon. In the latter case, the balloon will typically be filled with an electrolytic inflation material which permits it to be energized at a single polarity as part of a monopolar treatment system. The non-distensible, dimensionally stable expandable structures are used most often to position electrode arrays, either monopolar or bipolar, in a manner where their relative geometries do not vary. 10 [0018] A preferred electrode pattern on the non-distensible balloon or other dimensionally stable expandable structure comprises bipolar electrode pairs having a spacing therebetween which is no more than 3 mm. The bipolar electrode pairs may be aligned axially or circumferentially over the balloon or other expandable structure. Alternatively, the electrodes may be non-linear and arranged in a variety of other patterns so long as the 15 interelectrode spacing remains within the 3 mm requirement. [0019] As an alternative to the balloon, the expandable structure may comprise a frame which is deployable from the elongate member. Usually, the frame will expand to an arcuate frame having a shape and/or dimensions which engage only a portion of the full circumference of the esophageal wall (i.e. a partial circumferential section of the surface of 20 the esophagus). The arcuate frame can have a shape and/or dimensions configured to engage esophageal circumferential portions in the range from about 20 to 359", with preferred ranges of about 20 to 1800, about 20 to 90" or about 20 to 45". In this way, the expandable frame may be fully expanded with a preselected electrode spacing to permit controlled energy delivery. Sections of the esophagus may be then treated sequentially for fixed time periods, 25 where the total energy delivered to the mucosal wall is tightly controlled. Alternatively, the arcuate structure need not expandable, but can have a fixed shape configured to engage a selectable portion of the circumference of the esophageal wall. In such embodiments, the arcuate structure can be deployed using the elongate member or via another advancement means, e.g., an endoscope. 30 [0020] The systems of the present invention may also comprise thermal energy delivery structures, such as filaments, spherical radiators, cylindrical radiators, polygonal radiators, and the like. 6 WO 2005/070316 PCT/US2005/000432 BRIEF DESCRIPTION OF THE DRAWINGS [0021] FIG. 1 is a schematic view of portions of an upper digestive tract in a human. [0022] FIG. 1 A is a schematic view of an energy delivery system of the present invention used for the treatment of abnormal tissue in the esophagus. 5 [0023] FIG. 2 is a schematic view of a device of the invention, in an expanded mode, within an esophagus. [00241 FIG. 3 is a schematic view of a device of the invention. [0025] FIG. 4 is a detailed view of the device of FIG. 3. [00261 FIG. 5 is a view of a device of the invention. 10 [0027] FIG. 6 shows the electrode patterns of the device of FIG. 3. [0028] FIG. 7 shows electrode patterns that may be used with a device of the invention. [0029] FIG. 8 shows an alternative expandable structure and an electrode deployment device constructed in accordance with the principles of the present invention. [0030] FIGS. 9A and 9B illustrate use of the device of FIG. 8 for sequentially treating 15 circumferential segments of an esophagus according to the methods of the present invention. [0031] FIG. 10 illustrates yet another alternative electrode deployment apparatus according the principles of the present invention. [0032] FIG. 11 illustrates an alternative balloon electrode deployment device according to the principles of the present invention. 20 [0033] FIG. 12 illustrates a balloon inflatable with an electrically conductive inflation medium which can be utilized as a monopolar radiofrequency delivery device. [00341 FIG. 13 illustrates a balloon having a substantially continuous conductive layer formed over its surface and useable as a monopolar electrode deployment device. [0035] FIG. 14 illustrates a balloon composed of a dielectric material having substantially 25 continuous electrode structure formed over its interior surface. [0036] FIG. 15 illustrates a balloon having a plurality of axially elongate external electrodes formed over its exterior surface. 7 WO 2005/070316 PCT/US2005/000432 [00371 FIG. 16 illustrates a first thermal treatment catheter constructed in accordance with the principles of the present invention and comprising a cylindrical radiation heat element. [00381 FIG. 17 illustrates a thermal treatment catheter similar to that of FIG. 16, but including a spherical radiation heat element. 5 [00391 FIG. 18 illustrates a filament deployment catheter constructed in accordance with the principles of the present invention. [0040] FIGS. 19A and 19B illustrate use of the catheter of FIG. 18 and thermally treating an esophagus in accordance with the principles of the present invention. DETAILED DESCRIPTION OF THE INVENTION 10 [00411 Various inflammatory disorders result in human patients who experience retrograde flow of gastric or intestinal contents from the stomach 10, as shown in FIG. 1, into the esophagus 15. This flow is shown by arrows A and B in FIG. 1. Although the causation of these problems are varied, this retrograde flow may result in secondary disorders which require treatment independent of and quite different from treatments appropriate for the 15 primary disorder--such as disorders of the lower esophageal sphincter 18. One type of inflammatory disorder is known as Barrett's esophagus, in which the stomach acids, bile acids and enzymes regurgitated from the stomach and duodenum enter into the lower esophagus causing damage to the esophageal mucosa. Indeed, when this type of retrograde flow occurs frequently enough, damage may occur to esophageal epithelial cells 20. When normal 20 replacement of damaged cells is overcome by the rate of damage, then the result may be symptomatic destruction of the healthy squamous epithelium. When this occurs, the squamous cells can be replaced by columnar epithelium 30 of the lower esophageal passageway. It is well established that although some of the columnar cells may be benign, others may result in adenocarcinoma. Accordingly, attention has been focused on identifying 25 and removing this columnar epithelium in order to mitigate more severe implications for the patient. Examples of efforts to properly identify these growths, referred to as Barrett's epithelium or more generally as Barrett's esophagus, have included conventional visualization techniques known to practitioners in the field. Although certain techniques have been developed to characterize and distinguish such epithelium cells, such as disclosed in U.S. Pat. 30 Nos. 5,524,622 and 5,888,743, there has yet to be shown efficacious means of accurately removing undesired growths of this nature from portions of the esophagus to mitigate risk of malignant transformation.
WO 2005/070316 PCT/US2005/000432 [00421 Systems and methods for accomplishing this procedure according to this invention include the use of radiofrequency energy at conventional levels to accomplish injury or ablation of mucosal tissue, preferably without damage to submucosal tissue. Such treatment is designed to remove the columnar growths 30 from the portions of the esophagus 15 so 5 effected. In particular, such treatment is designed to initiate the growth of new, normal mucosal cells to replace the columnar growths 30 and other abnormal cells in the mucosal layer of the esophagus. Referring now to FIG. 1A, systems according to the present invention comprise an elongated member 32 having an energy delivery structure 34 at a distal end thereof. The energy delivery structure 34 is connected to an energy delivery supply 36, 10 such as a radiofrequency or other power supply, which controls and delivers energy through the structure into the mucosal wall of the lower esophagus just above the lower esophageal sphincter 18. The energy delivery supply 36 is adapted to deliver energy at relatively high levels of power for relatively short periods of time in order to achieve the shallow depth of treatment desired. Preferred energy levels and treatment times have been set forth 15 previously. [0043] In a specific embodiment, as shown in FIG. 2, an elongated flexible shaft 41 is provided for insertion into the body in any of various ways selected by the medical provider. The shaft may be preferably placed endoscopically, e.g. through the esophagus, or it may be placed surgically, or by other means. Energy distribution means is provided at a distal end 45 20 of the flexible shaft to provide appropriate energy for ablation as desired. It is recognized that energy of a preferred type includes radiofrequency energy, microwave energy, or photonic or radiant sources such as infrared or ultraviolet light, the latter possibly in combination with improved sensitizing agents. Photonic sources can include semiconductor emitters, lasers, and other such sources. It is also recognized that another embodiment of this invention may 25 utilize heatable fluid as an ablation energy medium. [0044] In one embodiment the flexible shaft comprises a coaxial cable surrounded by an electrical insulation layer and comprises a radiant energy distribution means located at its distal end. In one form of the invention, a positioning and distending device around the distal end of the instrument is of sufficient size to contact and expand the walls of the body cavity 30 in which it is placed (e.g. the esophagus) both in the front of the distribution means as well as on the sides of the distribution means. For example, the distal head of the instrument can be supported at a controlled distance from the wall of the esophagus by an expandable balloon member 52 so as to regulate and control the amount of energy transferred to the tissue 9 WO 2005/070316 PCT/US2005/000432 comprising the esophageal wall. The balloon is preferably bonded to a portion of the flexible shaft at a point spaced from the distal head means. [00451 Another embodiment comprises using the distending or expandable balloon member as the vehicle to deliver the ablation energy. A critical feature of this embodiment includes 5 means by which the energy is transferred from the distal head portion of the invention to the membrane comprising the balloon member. For example, one type of energy delivery means that may be appropriate and is incorporated herein in its entirety is shown in U.S. Pat. No. 5,713,942, in which an expandable balloon is connected to a power source which provides radiofrequency power having the desired characteristics to selectively heat the target tissue to 10 a desired temperature. The balloon 52 of the current invention may be constructed of an electroconductive elastomer such as a mixture of polymer, elastomer, and electroconductive particles, or it may comprise a non-distensible bladder having a shape and a size in its fully expanded form which will extend in an appropriate way to the tissue to be contacted. In another embodiment, an electroconductive member may be formed from an 15 electroconductive elastomer wherein an electroconductive material such as copper is deposited onto a surface and an electrode pattern is etched into the material and then the electroconductive member is attached to the outer surface of the balloon member. In one embodiment, the electroconductive member, e.g. the balloon member 52, has a configuration expandable in the shape to conform to the dimensions of the expanded (not collapsed) inner 20 lumen of the human lower esophageal tract. In addition, such electroconductive member may consist of a plurality of electrode area segments 58 having thermistor means or the like associated with each electrode segment by which the temperature from each of a plurality of segments is monitored and controlled by feedback arrangement. In another embodiment, it is possible that the electroconductive member may have means for permitting transmission of 25 microwave energy to the ablation site. In yet another embodiment, the distending or expandable balloon member may have means for carrying or transmitting a heatable fluid within one or more portions of the member so that the thermal energy of the heatable fluid may be used as the ablation energy source. [0046] A preferred device, such as that shown in FIG. 2, includes steerable and directional 30 control means, a probe sensor for accurately sensing depth of cautery, and appropriate alternate embodiments so that in the event it is desired to not place the electroconductive elements within the membrane forming the expandable balloon member, it is still possible to utilize the balloon member for placement and location control while maintaining the energy 1 n WO 2005/070316 PCT/US2005/000432 discharge means at a location within the volume of the expanded balloon member, such as at a distal energy distribution head of conventional design. 100471 In one embodiment, the system disclosed herein may be utilized as a procedural method of treating Barrett's esophagus. This method includes the detection and diagnosis of 5 undesired columnar epithelium within the esophagus. After determining that the portion or portions of the esophagus having this undesired tissue should be partially ablated, then the patient is prepared as appropriate according to the embodiment of the device to be utilized. Then, the practitioner prepares the patient as appropriate and inserts, in one embodiment, via endoscopic access and control, the ablation device shown and discussed herein through the 10 mouth of the patient. Further positioning of portions of the device occur until proper location and visualization identifies the ablation site in the esophagus. Selection and activation of the appropriate quadrant(s) or portion(s)/segment(s) on the ablation catheter member is performed by the physician, including appropriate power settings according to the depth of treatment desired. Additional settings may be necessary as further ablation is required at 15 different locations and/or at different depths within the patient's esophagus. Following the ablation, appropriate follow-up procedures as are known in the field are accomplished with the patient during and after removal of the device from the esophagus. The ablation treatment with ultraviolet light may also be accompanied by improved sensitizer agents, such as hematoporphyrin derivatives such as Photofrin* porfimer sodium, Johnson & Johnson 20 Corporation, New Brunswick, N.J.). [00481 In yet another embodiment of the method of the invention, the system disclosed herein may be utilized as a procedural method of treating dysplasia or cancerous tissue in the esophagus. After determining that the portion or portions of the esophagus having undesired tissue which should be partially ablated, then the patient is prepared as appropriate according 25 to the embodiment of the device to be utilized and treatment is provided as described above. 100491 In yet another method of the invention, the practitioner may first determine the length of the portion of the esophagus requiring ablation and then may choose an ablation catheter from a plurality of ablation catheters of the invention, each catheter having a different length of the electrode member associated with the balloon member. For example, if 30 the practitioner determined that 1 centimeter of the esophageal surface required ablation, an ablation catheter having 1 centimeter of the electrode member could be chosen for use in the 1 1 WO 2005/070316 PCT/US2005/000432 ablation. The length of the electrode member associated with the balloon member can vary in length from 0.5 cm to 20 cm, usually from 1 cm to 10 cm. [00501 In yet another embodiment, a plurality of ablation catheters wherein the radiant energy distribution means are associated with the balloon member can be provided wherein 5 the diameter of the balloon member when expanded varies from 12 mm to 50 mm. In this method, the practitioner will choose an ablation catheter having a diameter when expanded which will cause the esophagus to stretch and the mucosal layer to thin out, thus, reducing blood flow at the site of the ablation. The esophagus normally is 5 to 6 mm thick. In the method of the current invention, the esophagus is stretched and thinned so that the blood flow 10 through the esophageal vasculature is occluded. It is believed that by reducing the blood flow in the area of ablation, the heat generated by the delivered energy is less easily dispersed to other areas of the esophagus, thus constraining the energy to the ablation site. [0051] One means a practitioner may use to determine the appropriate diameter ablation catheter to use with a particular patient would be to use in a first step a highly compliant 15 balloon connected to pressure sensing means. The balloon would be inserted into the esophagus and positioned at the desired site of the ablation and inflated until an appropriate pressure reading was obtained. The diameter of the inflated balloon would be determined and an ablation device of the invention having a balloon member capable of expanding to that diameter would be chosen for use in the treatment. In the method of this invention, it is 20 desirable to expand the expandable electroconductive member such as a balloon sufficiently to occlude the vasculature of the submucosa, including the arterial, capillary or venular vessels. The pressure to be exerted to do so should therefore be greater than the pressure exerted by such vessels, typically from 1 psig to 20 psig, usually from 5 psig to 10 psig. [0052] Operation and use of a device of the invention are described as follows. The device 25 used is shown schematically in FIGS. 3 and 5 and a detailed view of the device is shown in FIG. 4. As shown in FIG. 5, the elongated flexible shaft 41 is connected to a multi-pin electrical connector 94 which is connected to the power source and includes a male luer connector 96 for attachment to a fluid source useful in expanding the expandable member. The expandable member has an electrode 98 wrapped around the circumference. The 30 expandable member of the device shown in FIGS. 3 and 4 further includes three different electrode patterns, the patterns of which are represented in greater detail in FIG. 6. Normally, only one electrode pattern would be used in a device of this invention. In this device, the 12 WO 2005/070316 PCT/US2005/000432 elongated flexible shaft 41 comprises six bipolar rings 62 with 2 mm separation at one end of the shaft (one electrode pattern), adjacent to the bipolar rings is a section of six monopolar bands or rectangles 65 with 1 mm separation (a second electrode pattern), and another pattern of bipolar axial interlaced finger electrodes 68 is positioned at the other end of the shaft (a 5 third electrode pattern). In this device, a null space 70 was positioned between the last of the monopolar bands and the bipolar axial electrodes. The catheter used in the study was prepared using a polyimide flat sheet of about 1 mil (0.001 ") thickness coated with copper. The desired electrode patterns were then etched into the copper. [00531 The electrode patterns of the invention may vary, other possible electrode patterns 10 are shown in FIG. 7 as 80, 84, 88, and 92, respectively. Pattern 80 is a pattern of bipolar axial interlaced finger electrodes with 0.3 mm separation. Pattern 84 includes monopolar bands with 0.3 mm separation. Pattern 88 includes bipolar rings with 0.3 mm separation. Pattern 92 is electrodes in a pattern of undulating electrodes with 0.2548 mm separation. [0054] In this case the electrodes were attached to the outside surface of an esophageal 15 dilation balloon 72 having a diameter of 18 mm. The device was adapted to use radiofrequency by attaching wires 74 as shown in FIG. 4 to the electrodes to connect them to the power source. [00551 The balloon was deflated and the catheter inserted into the esophagus as described below. In addition to the series of three different electrode patterns a number of different 20 energy factors were applied to the esophagus of a normal immature swine (about 25 kgs). First, an endoscope was passed into the esophagus of the subject. The device of the invention was placed into the distal esophagus using endoscopic guidance. The balloon member was inflated to press the electrodes against the esophageal mucosa. There was no indication that balloon dilation resulted in untoward effects on the esophagus. 25 [00561 Once the balloon member and electrodes were in place the first set of radiofrequency ("RF") applications were made. Following endoscopic evaluation of the treated areas, the device was withdrawn proximally. The placement of the device was evaluated endoscopically to assure a gap of normal tissue between the area of the first application and the second application, which gap will assure identification of the two 30 treatment areas during post procedure evaluations. The procedure was repeated a third time using a similar procedure to that of the second application. During the treatment the tissue impedance was monitored as an indicator of the progress of the treatment, high impedance WO 2005/070316 PCT/US2005/000432 being an indication of desiccation. Accordingly, the practitioner can determine through monitoring the tissue impedance when sufficient ablation has occurred. [00571 The RF energy can be applied to the electroconductive members in a variety of ways. In one embodiment, it is applied in a bipolar mode to bipolar rings through 5 simultaneous activation of alternating rings. In another embodiment, it is applied to the bipolar rings through sequential activation of pairs of rings. In another embodiment, the RF energy can be applied in monopolar mode through sequential activation of individual monopolar bands or simultaneous activation of the monopolar bands. 10 [00581 Various modifications to the above-mentioned treatment parameters can be made to optimize the ablation of the abnormal tissue. To obtain shallower lesions, the RF power applied may be increased while decreasing the treatment time. Also, the electrode patterns may be modified such as shown in FIG. 7 to improve the evenness and shallowness of the resulting lesions. The system and method of the invention may also be modified to 15 incorporate temperature feedback, resistance feedback and/or multiplexing electrode channels. [00591 As described above, the energy delivery structures have been adapted to deliver energy substantially simultaneously about the entire circumferential surface of a balloon or other expandable structure. When a balloon is inflated to different diameters, as will 20 typically be required when treating different patients having different esophageal sizes, it will be appreciated that the electrode spacing on a surface of the balloon will vary. In order to achieve repeatable electrode spacings and resulting energy fluxes, therefore, it is been necessary to preselect balloon sizes which are capable of fully expanding to a known, fixed diameter of an esophagus of a particular patient. In this way, the electrode spacings are 25 known, and energy delivery can be properly controlled. Such approaches are described in co pending application no. 10/754,444(Attorney Docket No. 021827-000400), the full disclosure of which is incorporated herein by reference. [0060] As an alternative to providing delivery structures having multiple sizes or otherwise maintaining a stable electrode spacing on an expansible balloon, the methods and apparatus 30 of the present invention optionally provide for an electrode deployment structure which is intended to cover only a circumferential and/or axial segment of the esophagus. In that way, 1 a WO 2005/070316 PCT/US2005/000432 the structure can have a fixed electrode spacing or density which can then be advanced and repositioned over the esophageal surface in order to achieve complete coverage for a desired treatment. [0061] Referring now to FIG. 8, a catheter 100 comprising an elongated member 102, 5 typically a tubular polymeric extrusion, includes a deployable arcuate electrode delivery structure 104. The arcuate frame can have a shape and/or dimensions configured to engage only a portion of the full circumference of the esophageal wall. In various embodiments, the engaged circumferential portion can be in the range from about 20 to 3590, with preferred ranges of about 20 to 180", about 20 to 900 or about 20 to 45". The structure may be 10 collapsed by drawing it into the tube 102 or deployed by advancing it distally from the tube, as shown in FIG. 8. Alternatively, the arcuate structure need not expandable, but can have a fixed shape configured to engage a selectable portion of the circumference of the esophageal wall. An electrode array 106 is formed on an outer surface of the arcuate support 104 so that it can be engaged against a circumferential section of the mucosal lining M of the lower 15 esophagus E, as shown in FIG. 9A. After radiofrequency energy is applied through the electrode array 106, a thin layer of mucosal tissue will be treated, as shown at TR1 in FIG. 9A. The arcuate deployment structure 104 may then be rotated so that the electrode array 106 is engaged against a new section of the mucosal wall of the esophagus E. A new region is treated, as shown at TR2 in FIG. 9B. By subsequently rotating the arcuate 20 deployment structure 106, the entire circumferential wall of the esophagus may be treated. It would also be possible to axially reposition the catheter 100 in order to treat successive axial sections of the esophagus as well. [00621 Referring now to FIG. 10, a treatment catheter 120, similar to catheter 100, may be provided with a pair of deployable arcuate structures 122 and 124. Electrode of arrays 126 25 may be formed on the outer and/or inner surfaces of the deployable arcuate structures. When formed over the inner surface, as shown in FIG. 10, the arcuate deployment structure will be composed of the dielectric material which permits radiofrequency treatment through the material into the esophageal wall. The use of a pair of deployment structures 122 and 124 reduces the total treatment time required when compared to the catheter 100 of FIG. 8. 30 [0063] A similar sequential treatment of the mucosal wall of an esophagus may be achieved using an inflatable balloon 130, as shown in FIG. 11. While most of the balloon 130 is formed from an elastomer, a non-distensible, dimensionally-stable portion 132 is formed as 15 WO 2005/070316 PCT/US2005/000432 part of the balloon and carries a plurality of electrodes 134 spaced-apart in a fixed and dimensionally stable manner. Thus, the elastomeric balloon may be fully inflated in an esophagus and used to treat a selectable circumferential section of the esophagus.m After an initial treatment is complete, the balloon may be rotated by a desired amount and used to treat 5 the next circumferential section. Such sequential treatment is continued until the entire circumference of the esophagus has been treated. The dimensionally stable portion can have selectable shapes and radial dimensions to treat different sized portions of the esophagus. Accordingly, in various embodiments, the non-distensible portion can be configured to engage and treat esophageal circumferential portions in the range from about 20 to 3590, with 10 preferred ranges of about 20 to 1800, about 20 to 900 or about 20 to 450. Also, the dimensionally stable portion can be flatter than the elastic portion. [00641 Referring now to FIGS. 12-15, a variety of monopolar radiofrequency electrode structures may be utilized in the systems of the present invention. Most simply, the treatment catheter may include a simple elastomeric or non-elastomeric balloon 150 formed from a 15 dielectric or electrically conductive polymer. The balloon 150 may be filled with a conductive inflation medium, such as saline 152. The entire balloon may then be energized by one pole of a radiofrequency power supply in order to delivery energy through the balloon wall into the esophagus in which it has been inflated. A conventional return electrode is mounted on the patient's skin, typically on the lower back, in order to complete the 20 "monopolar" treatment circuit. In FIG. 13, a simple elastomeric or non-distensible balloon 160 is covered with an electrically conductive coating 162 which can expand and deflate together with the balloon. The conductive layer 162 may be energized in a "monopolar" manner and utilized to treat a patient. In FIG. 14, a balloon 170, again either elastomeric or non-distensible, has an electrically conductive layer 172 formed on its interior surface. The 25 conductive surface may be energized in a "monopolar" manner in the balloon used to treat patients. The balloon 170 is formed from dielectric or electrically conductive material, allowing treatment of the esophagus. In FIG. 15, balloon 180 includes a plurality of axially or otherwise oriented electrodes 182 formed over its exterior surface. Electrodes 182 may be energized in a "monopolar" manner by attachment to one pole with a suitable radiofrequency 30 power supply. 100651 Turning now to FIGS. 16-19A/B, use of a thermal delivery catheter in the methods and systems of the present invention will be described. A catheter 200, as shown in FIG. 16, comprises a cylindrical radiator structure 202, preferably disposed between a pair of 16 WO 2005/070316 PCT/US2005/000432 expandable balloons 204 and 206 after the catheter has been located with its distal end within the lower esophagus. The balloons 204 and 206 may be inflated to center the energy delivery device 202 within the esophagus. The radiator 202 is then energized, typically by heating to a temperature of 1 000*C or above, in order to radiate energy outwardly to heat, injure, and in 5 some cases necrose, the tissue in the mucosal layer of the esophagus. [0066] Catheter 220 of FIG. 17 is very similar to catheter 200 described above, except that a spherical radiator 222 is positioned between the first and second balloons 224 and 226, respectively. [0067] Yet a further balloon catheter 240 is illustrated in FIG. 18, 19A, and 19B. The 10 catheter 240 comprises expansible balloons 242 and 244. Initially, the balloons are spaced together as shown in FIG. 18A. After deployment of catheter 240 within an esophagus E, as shown in FIG. 19A, the first balloon 242 may be inflated to anchor the distal end of the catheter. The body of catheter 240 is then pulled proximally, as shown in FIG. 19A, to expose a filament F for a preselected distance. As shown in FIG. 19B, once the filament F 15 has been adequately exposed, the second balloon 244 will be inflated and used to anchor the filament firmly in place. [00681 While a preferred embodiment of the present invention has been described, it should be understood that various changes, adaptations and modifications may be made therein without departing from the spirit of the invention and the scope of the appended claims. 20 1'7
Claims (26)
1. A system for treating mucosal tissue in an esophagus, said system comprising: 5 an elongated member; an arcuate energy delivery structure deployable from the elongated member and adapted to engage a circumferential section of a mucosal lining of the esophagus to deliver energy to the section, wherein the circumferential section is less than 3600; and means for delivering energy through the delivery structure to initiate regrowth of a to mucosal layer without substantial injury to a sub-mucosal layer underlying the mucosal layer.
2. A system as in claim 1, wherein the circumferential section is less than about 180 .
3. A system as in claim 1, wherein the circumferential section is less than about 15 90 .
4. A system as in claim 1, wherein the energy delivery structure is rotatable so as to sequentially treat different circumferential sections of the mucosal lining of the esophagus.
5. A system as in claim 1, wherein the energy delivery structure comprises an 20 expandable structure deployable from the elongated member, the expandable structure comprising an expandable balloon, and wherein at least a portion of the balloon is non distensible and dimensionally stable.
6. A system as in any one of claims 1 to 5, wherein the energy delivery structure further comprises an electrode array. 25
7. A system as in claim 6, wherein the energy delivery structure comprises an expandable balloon deployable from the elongated member and the electrode array comprises bipolar electrode pairs formed over a portion of the outer surface of the balloon, and wherein a spacing between the electrodes is no more than 3 mm.
8. A system as in claim 7, wherein the electrodes are aligned circumferentially 30 over the balloon. 19
9. A system as in claim 1, further including an expandable structure comprising a frame deployable from the elongated member and an electrode array formed over at least a portion of the frame. s
10. A system as in claim 9, wherein the frame comprises an arcuate surface which carries the electrodes to engage the circumferential section.
11. A system as in claim 10, wherein the frame comprises two oppositely facing arcuate surfaces.
12. A system as in claim 1, wherein the energy delivery structure comprises a 1o heating structure.
13. A system as in claim 12, wherein the heating structure comprises a radiation heat source.
14. A system as in claim 13, wherein the energy delivery structure further comprises a pair of expandable centering elements for centering the energy delivery 15 structure in the esophagus and disposed distally and proximally of the radiation heat source.
15. A system as in claim 1, wherein the energy delivery means comprises a photonic source.
16. A system as in claim 1, wherein the energy delivery means comprises a 20 radiofrequency power supply.
17. A system as in claim 16, wherein the radiofrequency power supply is adaptable to deliver an energy dosage in the range from I J/cm2 to 50 J/cm2 over a time period less than 5 seconds.
18. A system as in claim 16, wherein the radiofrequency power supply is 25 configured to deliver a pulse of energy to the energy delivery structure that produces a heating profile in esophageal tissue wherein engaged mucosal tissue is heated to a level sufficient to disable cell replication and submucosal tissue underlying the engaged mucosal tissue is not. 30 20
19. A system as in claim 1, wherein the energy delivery structure comprises an arcuate energy delivery structure deployable from the elongated member, the arcuate structure having a shape configured to engage only a partial circumferential section of the s surface of the esophagus.
20. A system as in claim 19, wherein the energy delivery structure comprises a radiofrequency electrode array coupled to the radiofrequency power supply, the array positioned on a surface of the energy delivery structure.
21. A system as in claim 20, wherein the energy pulse is less than about 1 second 10 in duration.
22. A system as in claim 1, wherein the energy delivery structure is configured to deliver at least one form of energy selected from the group consisting of radiofrequency energy, thermal energy, microwave energy, ultrasonic energy, infrared and ultraviolet radiation. is
23. A system as in claim 22, wherein the energy delivered comprises radiofrequency energy.
24. A system as in claim 1, wherein the energy delivery structure comprises an array of bipolar electrode pairs.
25. A system as in claim 24, wherein the electrodes have a width in the range 20 from 0.1 mm to 3 mm and are spaced apart by a distance in the range from 0.1 mm to 3 mm.
26. A system for treating mucosal tissue in an esophagus substantially as hereinbefore described with reference to any one of the embodiments as that embodiment is shown in Figures 8 to 11 of the accompanying drawings. 25 Dated 4 April, 2011 Barrx Medical, Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON & FERGUSON
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011221375A AU2011221375B2 (en) | 2004-01-09 | 2011-09-07 | System and method for treating abnormal epithelium in an esophagus |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/754,445 | 2004-01-09 | ||
US10/754,445 US20040215296A1 (en) | 1999-11-16 | 2004-01-09 | System and method for treating abnormal epithelium in an esophagus |
PCT/US2005/000432 WO2005070316A1 (en) | 2004-01-09 | 2005-01-07 | System and method for treating abnormal epithelium in an esophagus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2011221375A Division AU2011221375B2 (en) | 2004-01-09 | 2011-09-07 | System and method for treating abnormal epithelium in an esophagus |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2005206098A1 AU2005206098A1 (en) | 2005-08-04 |
AU2005206098B2 true AU2005206098B2 (en) | 2011-06-30 |
Family
ID=34807444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005206098A Ceased AU2005206098B2 (en) | 2004-01-09 | 2005-01-07 | System and method for treating abnormal epithelium in an esophagus |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040215296A1 (en) |
EP (1) | EP1708636B1 (en) |
AU (1) | AU2005206098B2 (en) |
CA (1) | CA2552787C (en) |
WO (1) | WO2005070316A1 (en) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060095032A1 (en) | 1999-11-16 | 2006-05-04 | Jerome Jackson | Methods and systems for determining physiologic characteristics for treatment of the esophagus |
EP1229849A1 (en) | 1999-11-16 | 2002-08-14 | Robert A. Ganz | System and method of treating abnormal tissue in the human esophagus |
US20040215235A1 (en) | 1999-11-16 | 2004-10-28 | Barrx, Inc. | Methods and systems for determining physiologic characteristics for treatment of the esophagus |
US7811282B2 (en) | 2000-03-06 | 2010-10-12 | Salient Surgical Technologies, Inc. | Fluid-assisted electrosurgical devices, electrosurgical unit with pump and methods of use thereof |
US6558385B1 (en) | 2000-09-22 | 2003-05-06 | Tissuelink Medical, Inc. | Fluid-assisted medical device |
US6689131B2 (en) | 2001-03-08 | 2004-02-10 | Tissuelink Medical, Inc. | Electrosurgical device having a tissue reduction sensor |
DE60134391D1 (en) | 2000-03-06 | 2008-07-24 | Salient Surgical Technologies | LIQUID DISPENSING SYSTEM AND CONTROL FOR ELECTRO-SURGERY EQUIPMENT |
US8048070B2 (en) | 2000-03-06 | 2011-11-01 | Salient Surgical Technologies, Inc. | Fluid-assisted medical devices, systems and methods |
JP2006504472A (en) | 2002-10-29 | 2006-02-09 | ティシューリンク・メディカル・インコーポレーテッド | Fluid-assisted electrosurgical scissors and method |
US7102758B2 (en) | 2003-05-06 | 2006-09-05 | Duke University | Fourier domain low-coherence interferometry for light scattering spectroscopy apparatus and method |
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
US7150745B2 (en) | 2004-01-09 | 2006-12-19 | Barrx Medical, Inc. | Devices and methods for treatment of luminal tissue |
US7727232B1 (en) | 2004-02-04 | 2010-06-01 | Salient Surgical Technologies, Inc. | Fluid-assisted medical devices and methods |
DE602005024952D1 (en) * | 2004-05-26 | 2011-01-05 | Medical Device Innovations Ltd | TISSUE DETECTION AND ABLATION DEVICE |
EP2460475A3 (en) | 2005-05-03 | 2013-02-27 | The University of Western Ontario | An oral device and kit for use in association therewith |
US9259267B2 (en) | 2005-09-06 | 2016-02-16 | W.L. Gore & Associates, Inc. | Devices and methods for treating cardiac tissue |
CA2626116C (en) * | 2005-10-11 | 2012-08-21 | Duke University | Systems and method for endoscopic angle-resolved low coherence interferometry |
US8537366B2 (en) * | 2005-10-11 | 2013-09-17 | Duke University | Systems and methods for endoscopic angle-resolved low coherence interferometry |
US20070106290A1 (en) * | 2005-11-08 | 2007-05-10 | Turano Thomas A | Conformable electrode catheter and method of use |
US8702694B2 (en) | 2005-11-23 | 2014-04-22 | Covidien Lp | Auto-aligning ablating device and method of use |
US7959627B2 (en) | 2005-11-23 | 2011-06-14 | Barrx Medical, Inc. | Precision ablating device |
US7997278B2 (en) | 2005-11-23 | 2011-08-16 | Barrx Medical, Inc. | Precision ablating method |
US20070299433A1 (en) * | 2006-06-27 | 2007-12-27 | C2 Therapeutics | Barrett's Esophagus Cryogenic Ablation System |
AU2007275018A1 (en) * | 2006-07-21 | 2008-01-24 | Oncoscope, Inc. | Protective probe tip, particularly for use on a fiber-optic probe used in an endoscopic application |
CA2666663C (en) * | 2006-10-18 | 2016-02-09 | Minnow Medical, Inc. | System for inducing desirable temperature effects on body tissue |
US9375246B2 (en) * | 2007-01-19 | 2016-06-28 | Covidien Lp | System and method of using thermal and electrical conductivity of tissue |
US8641711B2 (en) | 2007-05-04 | 2014-02-04 | Covidien Lp | Method and apparatus for gastrointestinal tract ablation for treatment of obesity |
US20080312644A1 (en) * | 2007-06-14 | 2008-12-18 | Boston Scientific Scimed, Inc. | Cryogenic balloon ablation instruments and systems |
US8784338B2 (en) | 2007-06-22 | 2014-07-22 | Covidien Lp | Electrical means to normalize ablational energy transmission to a luminal tissue surface of varying size |
AU2014200616B2 (en) * | 2007-07-06 | 2015-09-24 | Covidien Lp | Ablation in the Gastrointestinal Tract to Achieve Hemostasis and Eradicate Lesions With a Propensity for Bleeding |
US8251992B2 (en) | 2007-07-06 | 2012-08-28 | Tyco Healthcare Group Lp | Method and apparatus for gastrointestinal tract ablation to achieve loss of persistent and/or recurrent excess body weight following a weight-loss operation |
JP5835895B2 (en) * | 2007-07-06 | 2015-12-24 | コヴィディエン リミテッド パートナーシップ | Ablation in the gastrointestinal tract to achieve hemostasis and eradicate disorders with a tendency to bleed |
US8273012B2 (en) | 2007-07-30 | 2012-09-25 | Tyco Healthcare Group, Lp | Cleaning device and methods |
US8646460B2 (en) | 2007-07-30 | 2014-02-11 | Covidien Lp | Cleaning device and methods |
JP5579606B2 (en) * | 2007-09-13 | 2014-08-27 | デユーク・ユニバーシテイ | Apparatus, system and method for low coherence interferometry (LCI) |
CA2711643A1 (en) * | 2008-01-08 | 2009-07-16 | Oncoscope, Inc. | Systems and methods for tissue examination, diagnostic, treatment, and/or monitoring |
US10004657B2 (en) | 2008-02-08 | 2018-06-26 | The University Of Western Ontario | Method of brain activation |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
ES2701878T3 (en) | 2008-03-18 | 2019-02-26 | Circa Scient Llc | Temperature sensing device in large surface area |
US9833149B2 (en) | 2008-03-18 | 2017-12-05 | Circa Scientific, Llc | Methods, apparatus and systems for facilitating introduction of shaped medical instruments into the body of a subject |
CN102099000B (en) | 2008-04-15 | 2015-07-22 | 特鲁德尔医学国际公司 | Swallowing air pulse therapy mouthpiece and method for the use thereof |
CA2723806C (en) | 2008-05-09 | 2022-05-31 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
WO2010033940A1 (en) * | 2008-09-22 | 2010-03-25 | Minnow Medical, Inc | Inducing desirable temperature effects on body tissue using alternate energy sources |
US8372068B2 (en) | 2008-10-21 | 2013-02-12 | Hermes Innovations, LLC | Tissue ablation systems |
US8500732B2 (en) | 2008-10-21 | 2013-08-06 | Hermes Innovations Llc | Endometrial ablation devices and systems |
US9662163B2 (en) | 2008-10-21 | 2017-05-30 | Hermes Innovations Llc | Endometrial ablation devices and systems |
US8197476B2 (en) | 2008-10-21 | 2012-06-12 | Hermes Innovations Llc | Tissue ablation systems |
US8540708B2 (en) | 2008-10-21 | 2013-09-24 | Hermes Innovations Llc | Endometrial ablation method |
US8197477B2 (en) | 2008-10-21 | 2012-06-12 | Hermes Innovations Llc | Tissue ablation methods |
US8821486B2 (en) | 2009-11-13 | 2014-09-02 | Hermes Innovations, LLC | Tissue ablation systems and methods |
US8382746B2 (en) | 2008-11-21 | 2013-02-26 | C2 Therapeutics, Inc. | Cryogenic ablation system and method |
EP4193948A1 (en) | 2009-10-27 | 2023-06-14 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US8715278B2 (en) | 2009-11-11 | 2014-05-06 | Minerva Surgical, Inc. | System for endometrial ablation utilizing radio frequency |
EP4111995A1 (en) | 2009-11-11 | 2023-01-04 | Nuvaira, Inc. | Device for treating tissue and controlling stenosis |
US9289257B2 (en) | 2009-11-13 | 2016-03-22 | Minerva Surgical, Inc. | Methods and systems for endometrial ablation utilizing radio frequency |
US11896282B2 (en) | 2009-11-13 | 2024-02-13 | Hermes Innovations Llc | Tissue ablation systems and method |
US8529562B2 (en) | 2009-11-13 | 2013-09-10 | Minerva Surgical, Inc | Systems and methods for endometrial ablation |
US9823127B2 (en) | 2010-01-22 | 2017-11-21 | Duke University | Systems and methods for deep spectroscopic imaging of biological samples with use of an interferometer and spectrometer |
JP2013518256A (en) | 2010-01-22 | 2013-05-20 | デユーク・ユニバーシテイ | Multiple windowing scheme for spectroscopic coherence tomography (OCT) and Fourier domain low coherence interferometry |
US8517729B2 (en) | 2010-03-04 | 2013-08-27 | The University of Western Ontario and Trudell Medical International | Oral mouthpiece and method for the use thereof |
US9744339B2 (en) | 2010-05-12 | 2017-08-29 | Circa Scientific, Llc | Apparatus for manually manipulating hollow organs |
GB2496074B (en) * | 2010-07-13 | 2016-07-20 | Sandhill Scient Inc | Apparatus and method for detecting and measuring condition of esophageal mucosa and indications of gastroesophageal reflux disease |
US8956348B2 (en) | 2010-07-21 | 2015-02-17 | Minerva Surgical, Inc. | Methods and systems for endometrial ablation |
US9510897B2 (en) | 2010-11-05 | 2016-12-06 | Hermes Innovations Llc | RF-electrode surface and method of fabrication |
KR102423708B1 (en) | 2011-01-19 | 2022-07-20 | 프랙틸 헬쓰, 인코포레이티드 | Devices and methods for the treatment of tissue |
US10278774B2 (en) | 2011-03-18 | 2019-05-07 | Covidien Lp | Selectively expandable operative element support structure and methods of use |
US9028487B2 (en) | 2011-06-21 | 2015-05-12 | Cook Medical Technologies Llc | Expandable probe |
CA2846238C (en) | 2011-08-25 | 2016-06-07 | Covidien Lp | Systems, devices, and methods for treatment of luminal tissue |
WO2015077571A1 (en) | 2013-11-22 | 2015-05-28 | Fractyl Laboratories, Inc. | Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract |
KR102086184B1 (en) | 2012-02-27 | 2020-03-06 | 프랙틸 래브러토리스 인코포레이티드 | Heat ablation systems,devices and methods for the treatment of tissue |
EP4218884A3 (en) | 2012-04-19 | 2023-09-13 | Fractyl Health, Inc. | Tissue expansion devices, systems and methods |
ITMI20120651A1 (en) * | 2012-04-19 | 2013-10-20 | Stefano Bianchi | SYSTEM FOR THE ABLATION OF CARDIAC FABRIC, IN PARTICULAR OF ATRIAL FABRIC |
WO2014022436A1 (en) | 2012-07-30 | 2014-02-06 | Fractyl Laboratories Inc. | Electrical energy ablation systems, devices and methods for the treatment of tissue |
WO2014026055A1 (en) * | 2012-08-09 | 2014-02-13 | Fractyl Laboratories Inc. | Ablation systems, devices and methods for the treatment of tissue |
EP2903626A4 (en) | 2012-10-05 | 2016-10-19 | Fractyl Lab Inc | Methods, systems and devices for performing multiple treatments on a patient |
US9204921B2 (en) | 2012-12-13 | 2015-12-08 | Cook Medical Technologies Llc | RF energy controller and method for electrosurgical medical devices |
US9364277B2 (en) | 2012-12-13 | 2016-06-14 | Cook Medical Technologies Llc | RF energy controller and method for electrosurgical medical devices |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
EP2967956A4 (en) | 2013-03-15 | 2017-03-22 | Trudell Medical International | Oral mouthpiece and method for the use thereof |
US9901394B2 (en) | 2013-04-04 | 2018-02-27 | Hermes Innovations Llc | Medical ablation system and method of making |
EP3003461B1 (en) | 2013-06-04 | 2019-05-01 | Fractyl Laboratories, Inc. | Systems and devices for reducing the luminal surface area of the gastrointestinal tract |
US9649125B2 (en) | 2013-10-15 | 2017-05-16 | Hermes Innovations Llc | Laparoscopic device |
US20150119877A1 (en) * | 2013-10-25 | 2015-04-30 | Covidien Lp | Electrode ablation balloon catheter |
US10959774B2 (en) | 2014-03-24 | 2021-03-30 | Fractyl Laboratories, Inc. | Injectate delivery devices, systems and methods |
US9757535B2 (en) | 2014-07-16 | 2017-09-12 | Fractyl Laboratories, Inc. | Systems, devices and methods for performing medical procedures in the intestine |
US11185367B2 (en) | 2014-07-16 | 2021-11-30 | Fractyl Health, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
EP3169260B1 (en) | 2014-07-16 | 2019-09-25 | Fractyl Laboratories, Inc. | System for treating diabetes and related diseases and disorders |
US10492856B2 (en) | 2015-01-26 | 2019-12-03 | Hermes Innovations Llc | Surgical fluid management system and method of use |
WO2016175980A1 (en) | 2015-04-29 | 2016-11-03 | Csaba Truckai | Medical ablation device and method of use |
US9414878B1 (en) | 2015-05-15 | 2016-08-16 | C2 Therapeutics, Inc. | Cryogenic balloon ablation system |
US10531907B2 (en) | 2015-11-20 | 2020-01-14 | Covidien Lp | Devices, systems, and methods for treating ulcerative colitis and other inflammatory bowel diseases |
US10052149B2 (en) | 2016-01-20 | 2018-08-21 | RELIGN Corporation | Arthroscopic devices and methods |
US11253311B2 (en) | 2016-04-22 | 2022-02-22 | RELIGN Corporation | Arthroscopic devices and methods |
WO2017192480A2 (en) | 2016-05-02 | 2017-11-09 | Affera, Inc. | Therapeutic catheter with imaging |
KR102366631B1 (en) | 2016-05-20 | 2022-02-22 | 펜탁스 오브 아메리카 인코포레이티드 | Cryogenic ablation system with rotatable and translatable catheter |
EP3478197A4 (en) | 2016-07-01 | 2020-04-29 | Relign Corporation | Arthroscopic devices and methods |
US20190117971A1 (en) * | 2017-10-23 | 2019-04-25 | Cardiac Pacemakers, Inc. | Volume-filling leads for treatment of cancer with electric fields |
US20190117973A1 (en) * | 2017-10-23 | 2019-04-25 | Cardiac Pacemakers, Inc. | Electric field cancer therapy devices with feedback mechanisms and diagnostics |
US11291382B2 (en) | 2018-06-01 | 2022-04-05 | Diversatek Healthcare, Inc. | System and method for detecting and measuring the condition of intraluminal esophageal mucosa |
CN113727753A (en) | 2019-04-22 | 2021-11-30 | 波士顿科学国际有限公司 | Electrical stimulation device for cancer treatment |
EP3958960A1 (en) | 2019-04-23 | 2022-03-02 | Boston Scientific Scimed Inc. | Electrical stimulation with thermal treatment or thermal monitoring |
WO2020219517A2 (en) | 2019-04-23 | 2020-10-29 | Boston Scientific Scimed, Inc. | Electrical stimulation for cancer treatment with internal and external electrodes |
JP2022529374A (en) | 2019-04-23 | 2022-06-21 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Electrodes for electrical stimulation for cancer treatment |
US11554214B2 (en) | 2019-06-26 | 2023-01-17 | Meditrina, Inc. | Fluid management system |
CN115515674A (en) | 2020-02-24 | 2022-12-23 | 波士顿科学国际有限公司 | Systems and methods for treating pancreatic cancer |
US20210338316A1 (en) * | 2020-04-30 | 2021-11-04 | Ethicon, Inc. | Systems and methods for sealing cored or punctured tissue using inflatable balloon |
USD1014762S1 (en) | 2021-06-16 | 2024-02-13 | Affera, Inc. | Catheter tip with electrode panel(s) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055245A1 (en) * | 1998-04-30 | 1999-11-04 | Edwards Stuart D | Electrosurgical sphincter treatment apparatus |
US6112123A (en) * | 1998-07-28 | 2000-08-29 | Endonetics, Inc. | Device and method for ablation of tissue |
WO2000059393A1 (en) * | 1999-04-02 | 2000-10-12 | Genesis Medical, Inc. | Treating body tissue by applying energy and substances |
US20020156470A1 (en) * | 1998-12-29 | 2002-10-24 | John H. Shadduck | Surgical instruments for treating gastro-esphageal reflux |
US20030158550A1 (en) * | 1999-11-16 | 2003-08-21 | Ganz Robert A. | Method of treating abnormal tissue in the human esophagus |
WO2003092609A2 (en) * | 2002-04-30 | 2003-11-13 | Barrx, Inc. | System and method of treating abnormal tissue in an organ having a layered tissue structure |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK238080A (en) * | 1980-06-03 | 1981-12-04 | P Pless | GIANT STIMULATION PROBLEMS FOR ELECTRIC STIMULATION OF THE HEART |
US4930521A (en) * | 1989-03-17 | 1990-06-05 | Metzger William T | Variable stiffness esophageal catheter |
US5056532A (en) * | 1989-07-25 | 1991-10-15 | Medtronic, Inc. | Esophageal pacing lead |
US5542928A (en) * | 1991-05-17 | 1996-08-06 | Innerdyne, Inc. | Method and device for thermal ablation having improved heat transfer |
US5902272A (en) * | 1992-01-07 | 1999-05-11 | Arthrocare Corporation | Planar ablation probe and method for electrosurgical cutting and ablation |
US5336222A (en) * | 1993-03-29 | 1994-08-09 | Boston Scientific Corporation | Integrated catheter for diverse in situ tissue therapy |
US5800334A (en) * | 1993-06-17 | 1998-09-01 | Wilk; Peter J. | Intrapericardial assist device and associated method |
US5533958A (en) * | 1993-06-17 | 1996-07-09 | Wilk; Peter J. | Intrapericardial assist device and associated method |
US6405732B1 (en) * | 1994-06-24 | 2002-06-18 | Curon Medical, Inc. | Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors |
US6023638A (en) * | 1995-07-28 | 2000-02-08 | Scimed Life Systems, Inc. | System and method for conducting electrophysiological testing using high-voltage energy pulses to stun tissue |
US5591195A (en) * | 1995-10-30 | 1997-01-07 | Taheri; Syde | Apparatus and method for engrafting a blood vessel |
US6033397A (en) * | 1996-03-05 | 2000-03-07 | Vnus Medical Technologies, Inc. | Method and apparatus for treating esophageal varices |
US5833688A (en) * | 1997-02-24 | 1998-11-10 | Boston Scientific Corporation | Sensing temperature with plurality of catheter sensors |
US6547787B1 (en) * | 1997-03-13 | 2003-04-15 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
AU712738B2 (en) * | 1997-09-24 | 1999-11-18 | Eclipse Surgical Technologies, Inc. | Steerable catheter |
US6432104B1 (en) * | 1998-04-15 | 2002-08-13 | Scimed Life Systems, Inc. | Electro-cautery catherer |
US6325800B1 (en) * | 1998-04-15 | 2001-12-04 | Boston Scientific Corporation | Electro-cautery catheter |
US6358197B1 (en) * | 1999-08-13 | 2002-03-19 | Enteric Medical Technologies, Inc. | Apparatus for forming implants in gastrointestinal tract and kit for use therewith |
CA2384866C (en) * | 1999-09-28 | 2012-07-10 | Stuart D. Edwards | Treatment of tissue by application of energy and drugs |
US20040215235A1 (en) * | 1999-11-16 | 2004-10-28 | Barrx, Inc. | Methods and systems for determining physiologic characteristics for treatment of the esophagus |
DE60138319D1 (en) * | 2000-05-03 | 2009-05-20 | Bard Inc C R | Apparatus for imaging and ablation in electrophysiological procedures |
US7097644B2 (en) * | 2001-03-30 | 2006-08-29 | Ethicon Endo-Surgery, Inc. | Medical device with improved wall construction |
US20020183739A1 (en) * | 2001-03-30 | 2002-12-05 | Long Gary L. | Endoscopic ablation system with sealed sheath |
US20020177847A1 (en) * | 2001-03-30 | 2002-11-28 | Long Gary L. | Endoscopic ablation system with flexible coupling |
JP3722729B2 (en) * | 2001-06-04 | 2005-11-30 | オリンパス株式会社 | Endoscope treatment device |
CN100564534C (en) * | 2002-02-08 | 2009-12-02 | 金克克国际有限公司 | Produce the alcoholic acid method with carbon substrate |
US7137981B2 (en) * | 2002-03-25 | 2006-11-21 | Ethicon Endo-Surgery, Inc. | Endoscopic ablation system with a distally mounted image sensor |
US7252665B2 (en) * | 2003-10-31 | 2007-08-07 | Medtronic, Inc | Ablation of stomach lining to reduce stomach acid secretion |
US7150745B2 (en) * | 2004-01-09 | 2006-12-19 | Barrx Medical, Inc. | Devices and methods for treatment of luminal tissue |
-
2004
- 2004-01-09 US US10/754,445 patent/US20040215296A1/en not_active Abandoned
-
2005
- 2005-01-07 CA CA2552787A patent/CA2552787C/en active Active
- 2005-01-07 WO PCT/US2005/000432 patent/WO2005070316A1/en active Application Filing
- 2005-01-07 EP EP05705201.1A patent/EP1708636B1/en active Active
- 2005-01-07 AU AU2005206098A patent/AU2005206098B2/en not_active Ceased
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055245A1 (en) * | 1998-04-30 | 1999-11-04 | Edwards Stuart D | Electrosurgical sphincter treatment apparatus |
US6112123A (en) * | 1998-07-28 | 2000-08-29 | Endonetics, Inc. | Device and method for ablation of tissue |
US20020156470A1 (en) * | 1998-12-29 | 2002-10-24 | John H. Shadduck | Surgical instruments for treating gastro-esphageal reflux |
WO2000059393A1 (en) * | 1999-04-02 | 2000-10-12 | Genesis Medical, Inc. | Treating body tissue by applying energy and substances |
US20030158550A1 (en) * | 1999-11-16 | 2003-08-21 | Ganz Robert A. | Method of treating abnormal tissue in the human esophagus |
WO2003092609A2 (en) * | 2002-04-30 | 2003-11-13 | Barrx, Inc. | System and method of treating abnormal tissue in an organ having a layered tissue structure |
Also Published As
Publication number | Publication date |
---|---|
EP1708636A1 (en) | 2006-10-11 |
WO2005070316A1 (en) | 2005-08-04 |
AU2005206098A1 (en) | 2005-08-04 |
CA2552787A1 (en) | 2005-08-04 |
EP1708636A4 (en) | 2010-05-26 |
US20040215296A1 (en) | 2004-10-28 |
CA2552787C (en) | 2017-06-27 |
EP1708636B1 (en) | 2017-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005206098B2 (en) | System and method for treating abnormal epithelium in an esophagus | |
CA2825425C (en) | System and method of treating abnormal tissue in the human esophagus | |
CA2427978C (en) | System and method of treating abnormal tissue in the human esophagus | |
US9993281B2 (en) | Method and apparatus for gastrointestinal tract ablation for treatment of obesity | |
US8192426B2 (en) | Devices and methods for treatment of luminal tissue | |
AU2001263143A1 (en) | System and method of treating abnormal tissue in the human esophagus | |
US20040087936A1 (en) | System and method for treating abnormal tissue in an organ having a layered tissue structure | |
AU2013200263B2 (en) | System and method for treating abnormal epithelium in an esophagus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ COVIDIEN LP . |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |